Copyright
©2014 Baishideng Publishing Group Inc.
World J Gastroenterol. Nov 21, 2014; 20(43): 16275-16281
Published online Nov 21, 2014. doi: 10.3748/wjg.v20.i43.16275
Published online Nov 21, 2014. doi: 10.3748/wjg.v20.i43.16275
Figure 2 Comparison of cumulative survival rates between surgery group and transarterial embolization/transarterial chemoembolization group.
Cumulative survival rates in the surgery group (n = 22, median survival time of 13.61 mo; 95%CI: 7.49-19.72) and in the TAE/TACE group (n = 10, median survival time of 6.67 mo; 95%CI: 4.23-8.97). Cumulative survival rates at 4, 8 and 12 mo in the surgical group were significantly higher than in the TAE/TACE group (P < 0.01). TAE: Transarterial embolization; TACE: Transarterial chemoembolization.
- Citation: Zheng SZ, Liu DJ, Sun P, Yu GS, Xu YT, Gong W, Liu J. Feasibility and safety of sorafenib treatment in hepatocellular carcinoma patients with spontaneous rupture. World J Gastroenterol 2014; 20(43): 16275-16281
- URL: https://www.wjgnet.com/1007-9327/full/v20/i43/16275.htm
- DOI: https://dx.doi.org/10.3748/wjg.v20.i43.16275